Five health systems are coming together to form a new nonprofit generic drug company that will addressing rising generic drug costs and drug shortages at hospitals.
Generic drugs are supposed to help reduce the cost of healthcare by bringing down the price of medications, but that isn’t always the case. There have been recent instances where generic drugs, sometimes decades old, have received steep price increases.
A group of health systems are banding together to form their own nonprofit generic drug company to help address shortages and high-cost generics. Intermountain Healthcare is leading the collaboration with Ascension, SSM Health, and Trinity Health. The Department of Veterans Affairs is consulting with the group, but it has provided no funding. The 5 organizations represent more than 450 hospitals across the country.
“It’s an ambitious plan, but healthcare systems are in the best position to fix the problems in the generic drug market,” Marc Harrison, CEO and president of Intermountain Healthcare, said in a statement. “We witness, on a daily basis, how shortages of essential generic medications or egregious cost increases for those same drugs affect our patients. We are confident we can improve the situation for our patients by bringing much-needed competition to the generic drug market.”
The generic drug company is intended as an FDA-approved manufacturer. It will either directly manufacture drugs or sub-contract manufacturing. In addition to addressing rising costs of generics and providing more affordable options for patients, the company hopes to stabilize the supple of generic medications that have fallen into chronic shortage.
In April 2017, a study in JAMA1 highlighted the challenge of shortages of norepinephrine, a generic that is recommended as the first-line vasopressor for treatment of hypotension due to septic shock. The authors found that patients admitted to a hospital experiencing a shortage had higher in-patient mortality.
“The majority of drugs prone to shortage are, like norepinephrine, generic sterile injectable drugs with a short shelf life,” explained Julie M. Donohue, PhD, and Derek C. Angus, MD, MPH, in an accompanying editorial.2 They added that the shortage of norepinephrine in the study was caused by just 1 company reporting a manufacturing delay.
In November 2017, the American Hospital Association had written to FDA Commissioner Scott Gottlieb, MD, urging that he take action to resolve worsening shortages of small-volume parental solutions.
“We are concerned that the shortages of widely-used and critical products are quickly becoming a crisis and looming threat to the public’s health,” Thomas P. Nickels, executive vice president of government relations and public policy at AHA, wrote. “Therefore, we call on the FDA to both vigorously pursue strategies with the current manufacturers of these products and to seek out new suppliers in order to ameliorate the current shortage, as well as prevent such shortages from occurring in the future.”
The nonprofit generic drug company will be guided by an advisory committee that includes:
“For people in the United States, there is a dangerous gap today between the demand and supply of affordable prescription drugs,” said Richard J. Gilfillan, MD, CEO of Trinity Health. “If the only way to provide our communities with affordable drugs is to produce them ourselves, then that is what we will do. We look forward to more healthcare systems around the country joining this people-centered effort.”
References
1. Vail E, Gershengorn HB, Hua M, Walkey AJ, Rubenfeld G, Wunsch H. Association between US norepinephrine shortage and mortality among patients with septic shock. JAMA. 2017;317(14):1433—1442. doi:10.1001/jama.2017.2841.
2. Donohue JM, Angus DC. National shortages of generic sterile injectable drugs: norepinephrine as a case study of potential harm. JAMA. 2017;317(14):1415—1417. doi:10.1001/jama.2017.2826
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen